Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C

doi:10.4254/wjh.v9.i7.352

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9807)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

670

WORD

303

HTML

5245

Figures (1-1)

232

Tables (1-4)

409

Sum=6859

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1368

Download

1580

Sum=2948

Mar 8, 2017 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (46)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Mar 8, 2017; 9(7): 352-367
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.352

Full Size Figure Download Figure

Figure 1 Second-generation direct acting antivirals molecules.

Citation: Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367
URL: https://www.wjgnet.com/1948-5182/full/v9/i7/352.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i7.352